Nurix Therapeutics, Inc. NRIX
Set alert
At close · Oct 30
After hours · Oct 30, 4:21 PM ET
- YTD
- +41.28%
- 1 year
- +109.70%
- Open
- 26.90
- Prev close
- 27.12
- Mkt cap
- 2.93B
- Vol
- 2.31M
- Avg vol
- 1.70M
- EPS
- 2.43
- P/E
- 11.03
- Div yield
- 0.00%
More statistics
- Low
- 25.97
- High
- 26.92
- Forward P/E
- -21.01
- Beta
- 1.82
- Short ratio
- 10.30
- Inst. own
- 109.41%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jan 27, 2027
- 50-d avg
- 24.99
- 200-d avg
- 20.14
- 1y target
- 34.50
6M chart
Events in this range
- Jul 9, 2026Earnings: -0.81; estimate -0.72288; surprise -12.05%
- Oct 12, 2026Earnings: 4.73; estimate -0.60091; surprise 887.14%
- Oct 13, 2026Rating: Needham · Buy → Buy
- Oct 13, 2026Rating: Baird · Outperform → Outperform
- Oct 13, 2026Rating: Truist Securities · Buy → Buy
- Oct 13, 2026Rating: Oppenheimer · Outperform → Outperform
- Oct 13, 2026Rating: RBC Capital · Outperform → Outperform
- Oct 16, 2026Rating: HC Wainwright & Co. · Buy → Buy
Signals (23)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bullish | Oct 14, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 14, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 16, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| RSI: Overbought | Aug 10, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| RSI: Overbought | Jun 24, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 12, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | Jun 3, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 3, 2026 | 5 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| SMA: Bullish | May 21, 2026 | 5 months ago |
| MACD: Buy Signal | May 21, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 15, 2026 | 5 months ago |
| MACD: Sell Signal | May 1, 2026 | 6 months ago |
Key statistics
- Market cap
- 2.93B
- Enterprise value
- 1.98B
- Trailing P/E
- 11.03
- Forward P/E
- -21.01
- PEG ratio
- 0.00
- Price / sales
- 4.17
- Price / book
- 3.02
- EPS (TTM)
- 2.43
- Beta
- 1.82
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 42.01%
- Revenue (TTM)
- 701.94M
- Revenue growth
- 8426.30%
- Free cash flow
- 233.34M
- Total cash
- 1.05B
- Total debt
- 65.33M
- Return on equity
- 43.99%
- Shares outstanding
- 109.25M
- Short % of float
- 19.06%
- 50-day average
- 24.99
- 200-day average
- 20.14
Analyst view
Consensus: strong buy
- Target (low)
- 25.00
- Target (mean)
- 34.50
- Target (high)
- 45.00
- Strong buy5
- Buy8
- Hold1
- Sell0
- Strong sell0
Next earnings
Jan 27, 2027
Expected Jan 27, 2027. Consensus EPS estimate 1.51.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 27, 2027 | Nov 30, 2026 | -0.46 | — | — | — |
| Oct 12, 2026 | Aug 31, 2026 | -0.60091 | 4.73 | +5.33 | +887.14% |
| Jul 9, 2026 | May 31, 2026 | -0.72288 | -0.81 | -0.09 | -12.05% |
| Apr 8, 2026 | Feb 28, 2026 | -0.76 | -0.79 | -0.03 | -3.95% |
| Jan 28, 2026 | Nov 30, 2025 | -0.84 | -0.82 | +0.02 | +2.38% |
| Oct 9, 2025 | Aug 31, 2025 | -0.84 | -1.03 | -0.19 | -22.62% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 16, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 13, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 13, 2026 | Oppenheimer | main | Outperform | Outperform |
| Oct 13, 2026 | Truist Securities | main | Buy | Buy |
| Oct 13, 2026 | Baird | main | Outperform | Outperform |
| Oct 13, 2026 | Needham | reit | Buy | Buy |
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Pfizer Inc. for co-development and co-commercialization of multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nurixtx.com
News
- SpaceX To Rally Around 85%? Here Are 10 Top Analyst Forecasts For Friday
- HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $36
- Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways
- RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $35
- Oppenheimer Maintains Outperform on Nurix Therapeutics, Raises Price Target to $32
- Truist Securities Maintains Buy on Nurix Therapeutics, Lowers Price Target to $33
- Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36
- Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates
- CORRECTION: Nurix Therapeutics Q3 EPS $4.73 Beats $3.98 Estimate, Sales $673.064M Beat $411.481M Estimate
- Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Your note
Sign in to keep a note on NRIX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GREGORY JULIA PAIGE | Director | Sale | Oct 13, 2026 | 10,750 |
| HANSEN GWENN M | Officer | Sale | Oct 14, 2026 | 117,227 |
| RING CHRISTINE | Officer | Sale | Sep 1, 2026 | 9,110 |
| VAN HOUTE JOHANNES D | Chief Financial Officer | Sale | Aug 3, 2026 | 40,166 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.03% | 8,770,349 | 235.05M | Jun 29, 2026 |
| Vestal Point Capital, LP | 7.37% | 8,050,000 | 215.74M | Jun 29, 2026 |
| Deep Track Capital, Lp | 7.08% | 7,736,455 | 207.34M | Jun 29, 2026 |
| Rubric Capital Management LP | 6.62% | 7,227,778 | 193.70M | Jun 29, 2026 |
| FMR, LLC | 5.02% | 5,485,215 | 147.00M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 4.98% | 5,436,587 | 145.70M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.00% | 3,273,943 | 87.74M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.28% | 2,490,246 | 66.74M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.01% | 2,192,562 | 58.76M | Sep 29, 2026 |
| SmallCap World Fund Inc | 1.59% | 1,739,335 | 46.61M | Sep 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 1.58% | 1,729,986 | 46.36M | Sep 29, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 1.19% | 1,297,893 | 34.78M | Jun 29, 2026 |